Dublin, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The "General Anesthesia Drugs Market By Type of Drugs, By Route of Administration, By Surgery Type, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The general anesthesia drug market was valued at $5,400.5 million in 2021, and is projected to reach $7,736.3 million by 2031, registering a CAGR of 3.5% from 2022 to 2031.
The general anesthesia drug market is majorly driven by an increase in number of surgical procedures like hip and knee replacement surgery, cardiac surgery, general surgeries cancer surgeries, rise in number of geriatric population, increase in prevalence of osteoarthritis disease, and neurological disorders.
Moreover, an increase in the number of key players to formulate general anesthesia drug, propels the growth of the market. According to the rheumatology advisor, the annual number of total knee arthroplasty was predicted to increase by 56% from 2019 to 2020.
The demand for general anesthesia increases due to an increase in the number of knee arthroplasty surgery procedures. The knee and hip replacement procedures are majorly conducted under general anesthesia. Increase in prevalence of chronic disease, such as cardiovascular disease, cancer, and others is one of the major factor that boosts the growth of the market.
According to the Centers for disease control and prevention (CDC) approximately 659,000 population in the U.S. experienced death from heart disease each year. According to the same report in 2019, a total of 360,900 people died due to coronary heart disease. Every year in the U.S. approximately 805,000 population are diagnosed with heart attack among which 605,000 experienced their first heart attack. This factor upsurges the need for heart surgery, which further increases the need for general anesthesia.
On the contrary, risk associated with general anesthesia such as allergic reaction, nausea, and vomiting is anticipated to hinder the market growth during the forecast period. Advancement in R&D activities in general anesthesia in pharmaceutical and biotechnology sector propels the growth of the market. Rise in funding from government or non-government organization to provide surgical resources, encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the general anesthesia drug market.
Key Market Segments
By TYPE OF DRUGS
- Propofol
- Sevoflurane
- Desflurane
- Others
By ROUTE OF ADMNISTRATION
- Intravenous
- Inhalation
By SURGERY TYPE
- Knee and hip replacements
- Heart surgeries
- Cancer surgery
- General surgery
By END USER
- Hospital
- Ambulatory surgical centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- B. Braun Melsungen
- Baxter International Inc.
- Fresenius SE and Co. KGaA
- Hikma Pharmaceuticals plc
- Paion AG
- Pfizer Inc.
- Abbott Laboratories
- Abbvie Inc
- AstraZeneca plc
- Avet Pharmaceuticals Inc
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: GENERAL ANESTHESIA DRUGS MARKET, BY Type of Drugs
CHAPTER 5: GENERAL ANESTHESIA DRUGS MARKET, by Route of Administration
CHAPTER 6: GENERAL ANESTHESIA DRUGS MARKET, by Surgery Type
CHAPTER 7: GENERAL ANESTHESIA DRUGS MARKET, by End-user
CHAPTER 8: GENERAL ANESTHESIA DRUGS MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
For more information about this report visit https://www.researchandmarkets.com/r/mw0d2p
Attachment
